Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.
2011 ◽
Vol 29
(15_suppl)
◽
pp. 2537-2537
◽
Keyword(s):
Phase I
◽
2005 ◽
Vol 58
(1)
◽
pp. 107-116
◽